Forbion portfolio company, Calluna Pharma, was recently featured in a newly published article by BioCentury highlighting the next wave of therapeutic innovation in idiopathic pulmonary fibrosis (IPF).
Calluna’s CMO, Jonas Hallén, contributed to the discussion as the company advances CAL101, its first-in-class S100A4-targeting monoclonal antibody. Calluna is currently enrolling patients in the Phase II AURORA study evaluating CAL101 in IPF.
The article underscores the growing momentum behind novel approaches to address the significant unmet need in IPF, and the expanding body of evidence supporting new therapeutic strategies that may also have broader implications across fibrotic and inflammatory diseases.
Download the article here.